<p>Apellis Pharmaceuticals（纳斯达克：APLS - 获取免费报告）在周五向投资者发布的报告中，Stifel Nicolaus 将其目标价格从 55.00 美元下调至 48.00 美元，Benzinga 报道。该券商目前对该股票维持 “买入” 评级。Stifel Nicolaus 的目标价格意味着该公司当前价格有 93.22% 的潜在上涨空间。</p>
<ul>
<li>Beam Therapeutics 因基因治疗许可付款而大幅上涨</li>
</ul>
<p>其他几位研究分析师也对该公司发表了评论。William Blair 在周一的报告中重申了对 Apellis Pharmaceuticals 股票的 “跑赢大盘” 评级。Weiss Ratings 在周一的研究报告中重申了对 Apellis Pharmaceuticals 股票的 “卖出（d）” 评级。高盛集团将 Apellis Pharmaceuticals 的评级从 “中性” 下调至 “卖出”，并将其股票目标价从 26.00 美元下调至 18.00 美元，报告日期为 9 月 26 日。瑞穗证券在 11 月 3 日的报告中将 Apellis Pharmaceuticals 的目标价从 24.00 美元下调至 19.00 美元，并对该股票设定了 “中性” 评级。最后，TD Cowen 在 10 月 31 日的研究报告中将 Apellis Pharmaceuticals 的目标价从 50.00 美元下调至 45.00 美元，并对该股票设定了 “买入” 评级。共有 11 位股票研究分析师对该股票给予了买入评级，7 位给予了持有评级，2 位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “持有”，共识目标价为 33.94 美元。</p>
<p><strong>查看我们最新的 APLS 研究报告</strong></p>
<h2>Apellis Pharmaceuticals 股票下跌 1.4%</h2>
<ul>
<li>小型股是否预示着市场下跌？</li>
</ul>
<p>APLS 股票在周五开盘价为 24.84 美元。该公司的市值为 31.4 亿美元，市盈率为 78.97，贝塔值为 0.37。Apellis Pharmaceuticals 的 52 周低点为 16.10 美元，52 周高点为 35.57 美元。该公司的债务与股本比率为 0.90，速动比率为 3.10，流动比率为 3.54。该股票的 50 日移动平均线为 23.05 美元，200 日移动平均线为 22.56 美元。</p>
<p>Apellis Pharmaceuticals（纳斯达克：APLS - 获取免费报告）最近在 10 月 30 日（星期四）发布了其财报。该公司报告本季度每股收益为 1.67 美元，超出市场共识预期的 1.03 美元，超出幅度为 0.64 美元。Apellis Pharmaceuticals 的净利润率为 4.43%，股本回报率为 18.94%。该公司本季度的收入为 4.5858 亿美元，而市场共识预期为 3.6458 亿美元。去年同期，该公司每股收益为（0.46）美元。该公司的收入同比增长了 133.0%。作为一个整体，股票研究分析师预测 Apellis Pharmaceuticals 在本年度将发布每股收益为-1.7 美元。</p>
<h2>Apellis Pharmaceuticals 的内部买卖情况</h2>
<p>在相关消息中，首席财务官 Timothy Eugene Sullivan 在 10 月 21 日（星期二）出售了 10,000 股 Apellis Pharmaceuticals 股票。该股票以平均价格 28.03 美元出售，总交易额为 280,300.00 美元。交易后，首席财务官直接持有该公司 110,936 股股票，估值约为 3,109,536.08 美元。此次交易使其持股比例减少了 8.27%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。此外，首席法律顾问 David O. Watson 在 12 月 16 日（星期二）出售了 5,000 股该公司的股票。该股票以平均价格 24.49 美元出售，总价值为 122,450.00 美元。交易后，首席法律顾问持有该公司 103,730 股股票，估值约为 2,540,347.70 美元。此次交易使其持股比例减少了 4.60%。该销售的 SEC 文件提供了更多信息。在过去的 90 天里，内部人士出售了 56,092 股公司股票，价值为 1,366,652 美元。内部人士持有该公司 6.50% 的股份。</p>
<h2>机构投资者对 Apellis Pharmaceuticals 的看法</h2>
<p>机构投资者最近买入和卖出了该公司的股票。Parallel Advisors LLC 在第二季度将其在 Apellis Pharmaceuticals 的持股比例提高了 80.0%。Parallel Advisors LLC 目前持有该公司 1,924 股股票，价值 33,000 美元，此前在上个季度又购买了 855 股。Jones Financial Companies Lllp 在第三季度将其在 Apellis Pharmaceuticals 的持股比例提高了 206.8%。Jones Financial Companies Lllp 目前持有该公司 2,037 股股票，价值 46,000 美元，此前在上个季度又购买了 1,373 股。Osaic Holdings Inc.在第二季度将其在 Apellis Pharmaceuticals 的持股比例提高了 141.2%。Osaic Holdings Inc.目前持有该公司 2,682 股股票，价值 47,000 美元，此前在该期间又收购了 1,570 股。Allworth Financial LP 在第三季度将其在 Apellis Pharmaceuticals 的持股比例提高了 64.1%。Allworth Financial LP 目前持有该公司 2,194 股股票，价值 50,000 美元，此前在该期间又购买了 857 股。最后，Quantbot Technologies LP 在第三季度购买了 Apellis Pharmaceuticals 的新股份，价值 64,000 美元。对冲基金和其他机构投资者持有该公司 96.29% 的股份。</p>
<h2>关于 Apellis Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Apellis Pharmaceuticals, Inc.是一家商业阶段的生物制药公司，专注于通过抑制补体系统来发现、开发和商业化治疗自身免疫和炎症疾病的化合物。它提供 EMPAVELI 用于治疗阵发性夜间血红蛋白尿、C3 肾小管病和免疫复合物膜增生性肾小管炎，以及与造血干细胞移植相关的血栓性微血管病；并提供 SYFOVRE 用于治疗与年龄相关的黄斑变性和地理性萎缩（GA）引起的地理性萎缩。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，优于 Apellis Pharmaceuticals</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>Rocket Lab 的强劲反弹：近期动能背后的原因</li>
<li>投资石油股票的方式和原因</li>
<li>Jabil 在雷达下飞行——但可能会迎来 50% 的激增</li>
<li>消费者非必需品股票解析</li>
<li>高通的巨大反弹有一个隐患——这只股票能否继续上涨？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Apellis Pharmaceuticals 吗？</h2>
<p>在考虑 Apellis Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Apellis Pharmaceuticals 并不在名单上。</p>
<p>虽然 Apellis Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

APLS

<p>Stifel Nicolaus 将 Apellis Pharmaceuticals 的目标股价从 55 美元下调至 48 美元，维持 “买入” 评级。该股票从当前价格来看，潜在上涨幅度为 93.22%。其他分析师的评级则不一，普遍维持 “持有” 评级，目标股价为 33.94 美元。Apellis 报告了强劲的收益，收入同比增长 133%。内部交易活动包括首席财务官和总法律顾问的大量股票出售</p>

<p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) had its target price lowered by Stifel Nicolaus from $55.00 to $48.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the stock. Stifel Nicolaus' target price points to a potential upside of 93.22% from the company's current price.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（纳斯达克：APLS - 获取免费报告）在周五向投资者发布的报告中，Stifel Nicolaus 将其目标价格从 55.00 美元下调至 48.00 美元，Benzinga 报道。该券商目前对该股票维持 “买入” 评级。Stifel Nicolaus 的目标价格意味着该公司当前价格有 93.22% 的潜在上涨空间。</p>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治疗许可付款而大幅上涨</li>
</ul>
</div><p>Several other research analysts have also commented on the company. William Blair reissued an &#34;outperform&#34; rating on shares of Apellis Pharmaceuticals in a report on Monday. Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Apellis Pharmaceuticals in a research note on Monday. The Goldman Sachs Group cut Apellis Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;sell&#34; rating and cut their price objective for the stock from $26.00 to $18.00 in a report on Friday, September 26th. Mizuho decreased their price objective on Apellis Pharmaceuticals from $24.00 to $19.00 and set a &#34;neutral&#34; rating on the stock in a report on Monday, November 3rd. Finally, TD Cowen decreased their target price on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, October 31st. Eleven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $33.94.</p>
<div class="lb-trans"><p>其他几位研究分析师也对该公司发表了评论。William Blair 在周一的报告中重申了对 Apellis Pharmaceuticals 股票的 “跑赢大盘” 评级。Weiss Ratings 在周一的研究报告中重申了对 Apellis Pharmaceuticals 股票的 “卖出（d）” 评级。高盛集团将 Apellis Pharmaceuticals 的评级从 “中性” 下调至 “卖出”，并将其股票目标价从 26.00 美元下调至 18.00 美元，报告日期为 9 月 26 日。瑞穗证券在 11 月 3 日的报告中将 Apellis Pharmaceuticals 的目标价从 24.00 美元下调至 19.00 美元，并对该股票设定了 “中性” 评级。最后，TD Cowen 在 10 月 31 日的研究报告中将 Apellis Pharmaceuticals 的目标价从 50.00 美元下调至 45.00 美元，并对该股票设定了 “买入” 评级。共有 11 位股票研究分析师对该股票给予了买入评级，7 位给予了持有评级，2 位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “持有”，共识目标价为 33.94 美元。</p>
</div><p><strong>View Our Latest Research Report on APLS</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 APLS 研究报告</strong></p>
</div><h2>Apellis Pharmaceuticals Stock Down 1.4%</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股票下跌 1.4%</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否预示着市场下跌？</li>
</ul>
</div><p>APLS stock opened at $24.84 on Friday. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of 78.97 and a beta of 0.37. Apellis Pharmaceuticals has a fifty-two week low of $16.10 and a fifty-two week high of $35.57. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The stock has a fifty day moving average of $23.05 and a 200-day moving average of $22.56.</p>
<div class="lb-trans"><p>APLS 股票在周五开盘价为 24.84 美元。该公司的市值为 31.4 亿美元，市盈率为 78.97，贝塔值为 0.37。Apellis Pharmaceuticals 的 52 周低点为 16.10 美元，52 周高点为 35.57 美元。该公司的债务与股本比率为 0.90，速动比率为 3.10，流动比率为 3.54。该股票的 50 日移动平均线为 23.05 美元，200 日移动平均线为 22.56 美元。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The firm had revenue of $458.58 million during the quarter, compared to the consensus estimate of $364.58 million. During the same quarter last year, the company earned ($0.46) earnings per share. The company's revenue was up 133.0% on a year-over-year basis. As a group, equities research analysts predict that Apellis Pharmaceuticals will post -1.7 earnings per share for the current year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（纳斯达克：APLS - 获取免费报告）最近在 10 月 30 日（星期四）发布了其财报。该公司报告本季度每股收益为 1.67 美元，超出市场共识预期的 1.03 美元，超出幅度为 0.64 美元。Apellis Pharmaceuticals 的净利润率为 4.43%，股本回报率为 18.94%。该公司本季度的收入为 4.5858 亿美元，而市场共识预期为 3.6458 亿美元。去年同期，该公司每股收益为（0.46）美元。该公司的收入同比增长了 133.0%。作为一个整体，股票研究分析师预测 Apellis Pharmaceuticals 在本年度将发布每股收益为-1.7 美元。</p>
</div><h2>Insider Buying and Selling at Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 的内部买卖情况</h2>
</div><p>In related news, CFO Timothy Eugene Sullivan sold 10,000 shares of Apellis Pharmaceuticals stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $28.03, for a total transaction of $280,300.00. Following the transaction, the chief financial officer directly owned 110,936 shares in the company, valued at approximately $3,109,536.08. The trade was a 8.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, General Counsel David O. Watson sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $24.49, for a total value of $122,450.00. Following the transaction, the general counsel owned 103,730 shares of the company's stock, valued at approximately $2,540,347.70. This trade represents a 4.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 56,092 shares of company stock valued at $1,366,652. Insiders own 6.50% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Timothy Eugene Sullivan 在 10 月 21 日（星期二）出售了 10,000 股 Apellis Pharmaceuticals 股票。该股票以平均价格 28.03 美元出售，总交易额为 280,300.00 美元。交易后，首席财务官直接持有该公司 110,936 股股票，估值约为 3,109,536.08 美元。此次交易使其持股比例减少了 8.27%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。此外，首席法律顾问 David O. Watson 在 12 月 16 日（星期二）出售了 5,000 股该公司的股票。该股票以平均价格 24.49 美元出售，总价值为 122,450.00 美元。交易后，首席法律顾问持有该公司 103,730 股股票，估值约为 2,540,347.70 美元。此次交易使其持股比例减少了 4.60%。该销售的 SEC 文件提供了更多信息。在过去的 90 天里，内部人士出售了 56,092 股公司股票，价值为 1,366,652 美元。内部人士持有该公司 6.50% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Apellis Pharmaceuticals 的看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 80.0% during the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock valued at $33,000 after buying an additional 855 shares during the last quarter. Jones Financial Companies Lllp increased its position in shares of Apellis Pharmaceuticals by 206.8% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company's stock valued at $46,000 after purchasing an additional 1,373 shares during the last quarter. Osaic Holdings Inc. raised its stake in shares of Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company's stock valued at $47,000 after acquiring an additional 1,570 shares during the period. Allworth Financial LP boosted its position in shares of Apellis Pharmaceuticals by 64.1% during the third quarter. Allworth Financial LP now owns 2,194 shares of the company's stock valued at $50,000 after buying an additional 857 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in Apellis Pharmaceuticals in the third quarter worth $64,000. Hedge funds and other institutional investors own 96.29% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该公司的股票。Parallel Advisors LLC 在第二季度将其在 Apellis Pharmaceuticals 的持股比例提高了 80.0%。Parallel Advisors LLC 目前持有该公司 1,924 股股票，价值 33,000 美元，此前在上个季度又购买了 855 股。Jones Financial Companies Lllp 在第三季度将其在 Apellis Pharmaceuticals 的持股比例提高了 206.8%。Jones Financial Companies Lllp 目前持有该公司 2,037 股股票，价值 46,000 美元，此前在上个季度又购买了 1,373 股。Osaic Holdings Inc.在第二季度将其在 Apellis Pharmaceuticals 的持股比例提高了 141.2%。Osaic Holdings Inc.目前持有该公司 2,682 股股票，价值 47,000 美元，此前在该期间又收购了 1,570 股。Allworth Financial LP 在第三季度将其在 Apellis Pharmaceuticals 的持股比例提高了 64.1%。Allworth Financial LP 目前持有该公司 2,194 股股票，价值 50,000 美元，此前在该期间又购买了 857 股。最后，Quantbot Technologies LP 在第三季度购买了 Apellis Pharmaceuticals 的新股份，价值 64,000 美元。对冲基金和其他机构投资者持有该公司 96.29% 的股份。</p>
</div><h2>About Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Apellis Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.是一家商业阶段的生物制药公司，专注于通过抑制补体系统来发现、开发和商业化治疗自身免疫和炎症疾病的化合物。它提供 EMPAVELI 用于治疗阵发性夜间血红蛋白尿、C3 肾小管病和免疫复合物膜增生性肾小管炎，以及与造血干细胞移植相关的血栓性微血管病；并提供 SYFOVRE 用于治疗与年龄相关的黄斑变性和地理性萎缩（GA）引起的地理性萎缩。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Rocket Lab's Sharp Rebound: What's Behind the Recent Momentum</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Jabil Is Flying Under the Radar—But a 50% Surge May Be Coming</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Qualcomm’s Monster Rally Has a Catch—Can the Stock Keep Climbing?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，优于 Apellis Pharmaceuticals</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>Rocket Lab 的强劲反弹：近期动能背后的原因</li>
<li>投资石油股票的方式和原因</li>
<li>Jabil 在雷达下飞行——但可能会迎来 50% 的激增</li>
<li>消费者非必需品股票解析</li>
<li>高通的巨大反弹有一个隐患——这只股票能否继续上涨？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=APLS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Apellis Pharmaceuticals 吗？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Apellis Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Apellis Pharmaceuticals 并不在名单上。</p>
</div><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Apellis Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Stifel Nicolaus 将 Apellis Pharmaceuticals（NASDAQ:APLS）的目标股价下调至 48.00 美元